Seminars in Oncology 1990-10-01

Fludarabine phosphate therapy in other lymphoid malignancies.

H M Kantarjian, J R Redman, M J Keating

Index: Semin. Oncol. 17(5 Suppl 8) , 66-70, (1990)

Full Text: HTML

Abstract

The promising results obtained with Fludara I.V. (fludarabine phosphate) treatment in the common indolent B-cell neoplasms have led to their further evaluation in other unusual B-cell malignancies, in Hodgkin's disease, and in T-cell diseases. A significant response rate has been found among patients with macroglobulinemic lymphoma, those with prolymphocytic leukemia or prolymphocytoid variant of chronic lymphocytic leukemia, and those with mycosis fungoides. The limited therapeutic data in hairy-cell leukemia and in Hodgkin's disease are also interesting.

Related Compounds

  • Fludarabine phosph...

Related Articles:

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

2015-01-01

[Cancer Chemother. Pharmacol. 75(1) , 67-75, (2015)]

Fludarabine phosphate in lymphoma: an important new therapeutic agent.

1996-01-01

[Cancer Treat. Res. 85 , 3-14, (1996)]

Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.

1993-01-01

[Cancer Treat. Res. 64 , 105-19, (1993)]

Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.

1991-01-01

[J. Clin. Oncol. 9(1) , 175-88, (1991)]

Metabolism and action of fludarabine phosphate.

1990-10-01

[Semin. Oncol. 17(5 Suppl 8) , 3-17, (1990)]

More Articles...